Streetbeat News

Earnings

VYGR

Voyager Therapeutics (NASDAQ:VYGR) reported Q4 earnings with an EPS of $1.25, surpassing the estimated -$0.29 by 531.0%. Revenue increased by $91.61 million from the same period last year. Despite missing EPS estimates last quarter by $0.01, the share price increased by 5.0% the following day. The company has shown varied performance over the past quarters, with significant fluctuations in EPS and revenue.

Portfolio Pulse from Benzinga Insights

February 28, 2024 | 9:30 pm

MRAM

Everspin Technologies forecasts its Q1 2024 GAAP EPS to be around $0.5, significantly higher than the estimated $0.06. However, its revenue projection of $13.5M-$14.5M falls short of the expected $15.60M.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 9:30 pm

ADMA

ADMA Biologics (NASDAQ:ADMA) reported Q4 earnings with an EPS of $0.04, doubling the estimated $0.02 and marking a significant revenue increase of $23.92 million from the previous year. This follows a trend of beating EPS estimates and subsequent share price increases.

Portfolio Pulse from Benzinga Insights

February 28, 2024 | 9:30 pm

ATRO

Astronics (NASDAQ:ATRO) reported Q4 earnings with an EPS of $0.2, missing estimates by -9.0% and showing a revenue increase of $37.14 million from the previous year. This follows a pattern of missed EPS estimates in previous quarters, notably last quarter's miss leading to a 13.0% share price drop the next day.

Portfolio Pulse from Benzinga Insights

February 28, 2024 | 9:30 pm

XPER

Xperi Corporation (NYSE:XPER) reported Q4 earnings with an EPS of $0.11, surpassing the estimated $0.05 by 120%. Revenue increased by $1.70 million from the previous year. The company had previously beaten EPS estimates in Q3 2023, leading to a 9% share price increase the following day. Xperi's performance over the past quarters shows consistent revenue growth and EPS improvements.

Portfolio Pulse from Benzinga Insights

February 28, 2024 | 9:30 pm

BRP

BRP Group (NASDAQ:BRP) reported Q4 earnings with a 27.0% beat on estimated EPS, reporting $0.14 versus an estimate of $0.11. Revenue increased by $38.60 million from the same period last year. Despite beating last quarter's EPS estimate, the share price dropped by 12.0% the next day. Historical earnings performance shows fluctuating EPS and revenue growth.

Portfolio Pulse from Benzinga Insights

February 28, 2024 | 9:30 pm

CSTL

Castle Biosciences (NASDAQ:CSTL) reported Q4 2023 GAAP EPS of $(0.10), surpassing the $(0.61) estimate, with sales of $66.12M exceeding the $56.28M forecast. This represents a 72.47% increase in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 9:30 pm

SDGR

Schrodinger's shares have declined following the announcement of mixed financial results for the fourth quarter.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 9:30 pm

XPER

Xperi reported Q4 2023 adjusted EPS of $0.11, surpassing the $0.05 estimate, but its sales of $137.23M fell short of the $140.18M forecast. This represents a 1.26% increase in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 9:30 pm

DV

DoubleVerify's stock is trading lower following the announcement of their Q4 financial results.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 9:29 pm